This is an aggregated industry headline. Read the full story at FierceBiotech →
Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal
QuantumCell has licensed AlzeCure Pharma's Alzheimer's disease platform and lead asset for $12 million upfront, bagging a potentially symptom-relieving drug candidate that is on the cusp of phase 2.
By FierceBiotech
· Jul 1, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Tara Sparks was just days away from starting her new job at Novo Nordisk in February 2025 when she gathered wi…
The WeekBriefing
FDA approved Orca Bio’s Tregzi, the first allogeneic regulatory T cell therapy for blood cancer patients needi…
The WeekPharmaceutical Technology ↗
AbbVie presented new results from the Phase III ECLIPSE trial (NCT06241313) at this year's Congress of the Eur…